Cantargia AB: Cantargia reaches recruitment milestone and fo

Cantargia AB: Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies

LUND, Sweden, Oct. 14, 2022 /PRNewswire/ -- Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today announced that the clinical trials CAPAFOUR and CESTAFOUR have enrolled enough patients to

Related Keywords

Sweden , Stockholm , Prnewswire Cantargia , , Nasdaq Stockholm , Cantargia , Beaches , Recruitment , Milestone , Focuses , Adunolimab , Development , Pcoming , Randomized , Studies ,